Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0311277 (
abdominal obesity
)
2,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Metabolic syndrome (MetS) is an important risk factor for the development of type-2 diabetes and coronary artery disease. We aimed to compare the MetS prevalence in patients with
borderline personality disorder
(
BPD
) with comparison subjects followed in primary care from a similar region. One hundred and thirty-five
BPD
patients according to DSM-IV diagnostic criteria were compared to 1009 subjects from primary care. We used the American Heart Association/National Heart, Lung and Blood Institute criteria to determine the rate of MetS. The age-standardized prevalence of MetS was more than double in patients with
BPD
compared to comparison subjects (23.3 vs. 10.6 %, p < 0.05). Regarding individual MetS criteria, hyperglycemia was significantly more prevalent in both genders (p < 0.05).
Abdominal obesity
(p < 0.05) and hypertriglyceridemia (p < 0.05) were significantly higher only in women with
BPD
. Within
BPD
patients, an increased rate of MetS was associated with higher BMI (p = 0.004), age (p = 0.03), treatment with second-generation antipsychotics (quetiapine, olanzapine and clozapine; p = 0.032), dysthymia (p = 0.031), panic disorder (p = 0.032), benzodiazepine dependency (p = 0.015) and binge eating disorder p = 0.02). Our results demonstrate an increased MetS rate, dysregulated glucose and lipid metabolism in patients with
BPD
. Cardiometabolic monitoring and careful screening for physical health conditions among people with
BPD
is warranted.
...
PMID:Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study. 2277 77
In recent years, accumulating more and more evidence demonstrating the programming effects of intrauterine development on the subsequent health of the individual. Intrauterine fetal hypotrophy is a consequence of the wide range of pathological processes in different periods of pregnancy. It is the second leading cause of perinatal death after prematurity. Newborns from similar pathological pregnancies are often leaked premature baby and/or small for gestational age (SGA). Premature baby children have not only complicated and postnatal adaptation problems in the neonatal period, but many diseases occurring in later life: 1. Disorders in postnatal growth. 2. Neurological and intellectual consequences of IUH in term children (hyperactivity disorders attention, impaired fine motor skills, speech problems, risk of cerebral palsy). 3. Neurological and intellectual consequences of prematurity IUH (cognitive impairment in children with low birth weight, short stature at birth, and small head circumference for gestational age). 4. Metabolic syndrome (dyslipidemia,
abdominal obesity
, hypertension and high blood sugar). 5. Abnormal sexual development (hyperandrogenism, polycystic ovary syndrome in girls, reduced testicular size and lower testosterone levels in boys. 6. Other complications associated with intrauterine hypotrophy cardiovascular renal, pulmonary complications (
BPD
) disorders in vision, sensory neural hearing loss.
...
PMID:[Intrauterine hypotrophy and programming the health status. Late problems in newborns with intrauterine hypotrophy]. 2380 79